Physician profile
Elliot Levine
NPI 1104141415
$7,845.19
in general payments reported to CMS, 2019-2025
30 companies · $443 in 2025
The $443 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $506 · 2021: $234 · 2022: $4,177 · 2023: $417 · 2024: $495 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.91 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,003.38 | 2022 | |
| Medtronic Vascular, INC. | $1,031.77 | 2019 | |
| Abbott Laboratories | $615.44 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console, Cardiomems |
| Pfizer INC. | $246.26 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $229.37 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $196.94 | 2025 | Mounjaro, Zepbound |
| Actelion Pharmaceuticals US, INC. | $188.86 | 2024 | Opsumit, Uptravi |
| Abiomed | $169.77 | 2021-2025 | Impella |
| United Therapeutics Corporation | $141.97 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $127.26 | 2020-2023 | Camzyos |
| Cardiovascular Systems INC. | $126.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $85.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $82.49 | 2020-2025 | Airsupra, Farxiga |
| Lundbeck LLC | $81.20 | 2024 | Rexulti |
| Alnylam Pharmaceuticals INC. | $78.80 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.28 | 2024-2025 | Verquvo |
| Atricure, INC. | $52.65 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.64 | 2024 | Lifevest |
| Ibsa Pharma INC. | $39.71 | 2020 | |
| Endo Pharmaceuticals INC. | $37.17 | 2019 | |
| Bridgebio Pharma, INC. | $29.28 | 2025 | Attruby |
| Kyowa Kirin, INC. | $28.49 | 2025 | |
| Insulet Corporation | $24.80 | 2025 | Omnipod |
| Ethicon US, LLC | $24.40 | 2022 | |
| Sun Pharmaceutical Industries INC. | $20.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.81 | 2021 | |
| Seqirus USA INC | $15.43 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Sensible Medical Innovations INC | $14.88 | 2019 | |
| Abbvie INC. | $12.67 | 2021 | |
| Kci USA, INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.